Department of Clinical Pharmacology, Seth, GS Medical College & KEM Hospital, Mumbai, India.
Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
J Clin Pharmacol. 2022 Nov;62(11):1403-1411. doi: 10.1002/jcph.2092. Epub 2022 Jun 30.
Healthcare workers (HCWs) and frontline workers were recommended hydroxychloroquine (HCQ) 400 mg twice a day on day 1, followed by 400 mg once weekly for the next 7 weeks, as prophylaxis against COVID-19. There was limited information on the population pharmacokinetics (popPK) of HCQ in an Indian setting when administered for prophylaxis against COVID-19, and hence this study was proposed. It was a multicentric prospective study conducted at 3 sites in India wherein HCWs who were already on HCQ prophylaxis, who were about to start prophylaxis or who had stopped the prophylaxis for any reason were enrolled. Each participant gave 2 to 6 blood samples at different time points and whole-blood HCQ concentrations were assayed using liquid chromatography with tandem mass spectrometry (LC MS/MS). popPK analysis was performed using PUMAS 1.1.0. A total of N = 338 blood samples from N = 121 participants were included in the popPK analysis. A 2-compartment structural model with linear elimination was able to explain the observed data. Body weight was found to be a significant covariate influencing drug clearance. The final model was assessed using goodness-of-fit plots, a visual predictive check and a bootstrap, all of which confirmed that the model was appropriate. Simulations based on the current regimen showed that trough values were below the half-maximal effective concentration (EC50) of 0.7 μmol against COVID-19. A new weight-based dosage regimen was proposed to maintain the trough concentration above the EC50 threshold.
医护人员(HCWs)和一线工作人员被建议在第 1 天每天服用羟氯喹(HCQ)400mg,分两次服用,然后在接下来的 7 周内每周服用 400mg,作为预防 COVID-19 的措施。在印度,当用于预防 COVID-19 时,关于 HCQ 的群体药代动力学(popPK)的信息有限,因此提出了这项研究。这是一项在印度三个地点进行的多中心前瞻性研究,其中已经接受 HCQ 预防治疗的 HCWs、即将开始预防治疗或因任何原因停止预防治疗的 HCWs 都被纳入研究。每个参与者在不同时间点采集 2 到 6 份血样,使用液相色谱-串联质谱法(LC-MS/MS)测定全血 HCQ 浓度。popPK 分析使用 PUMAS 1.1.0 进行。共纳入了来自 121 名参与者的 338 份血样进行 popPK 分析。一个具有线性消除的两室结构模型能够解释观察到的数据。体重被发现是影响药物清除率的重要协变量。使用拟合度图、可视化预测检查和自举法对最终模型进行评估,所有这些都证实了模型的适用性。基于当前方案的模拟表明,谷值浓度低于 COVID-19 的半最大有效浓度(EC50)0.7μmol。提出了一种新的基于体重的剂量方案,以维持谷值浓度高于 EC50 阈值。